Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation
This report summarises the results from two epidemiological studies conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium undertaken in eight European Union (EU)/European Economic Area (EEA) countries in order to investigate a possible association between an unexpected increase in narcolepsy cases following the use of influenza A(H1N1)pdm09 vaccines. Narcolepsy is an underdiagnosed disease of widely unknown etiology.
Overrepresentation of influenza A(H1N1)pdm09 virus among severe influenza cases in the 2011/12 season in four European countries
Beaute, J., Broberg, E., Plata, F., Bonmarin, I., O'Donnell, J., Delgado, C., Boddington, N., Snacken, R.
Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA): Influenza
This report which is part of the RAGIDA project (Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft) provides viable options for decision-makers when faced with the choice of whether to contact trace air travellers and crew that were potentially exposed to infectious diseases during a flight.
- Avian influenza virus
- Infectious diseases on aircrafts
- Influenza A (H1N1)2009
- Influenza A(H5N1) virus
- Influenza A(H5N2) virus
- Influenza A(H5N8) virus
- Influenza A(H7N9) virus
- Influenza in humans, avian origin
- Influenza in humans, pandemic
- Influenza in humans, seasonal
- Influenza in humans, swine origin
- Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA)
- Travellers' health
Communicable disease threats report, 7-13 April 2019, Week 15
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period from 24-30 March 2019 and includes updates on Ebola virus disease and influenza.
Guide to public health measures to reduce the impact of influenza pandemics in Europe – ‘The ECDC Menu’
This document presents a menu of possible public measures to be taken during influenza pandemics, giving public health and scientific information on what is known or can be said about their likely effectiveness, costs (direct and indirect), acceptability, public expectations and other more practical considerations. The ‘ECDC Menu’ aims to help EU Member States and institutions, individually or collectively, decide which measures they will apply.
Understanding the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines
This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
EMA's Committee for Medicinal Products for Human Use (CHMP) issues opinion on narcolepsy and vaccination with Pandemrix®Archived
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).